Background-Genetic testing identifies sarcomere mutation carriers (Gϩ) before clinical diagnosis of hypertrophic cardiomyopathy (HCM), allowing characterization of initial disease manifestations. Previous studies demonstrated that impaired relaxation develops before left ventricular hypertrophy (LVH). The precise impact of sarcomere mutations on systolic function in early and late disease is unclear. Methods and Results-Comprehensive echocardiography with strain imaging was performed on 146 genotyped individuals with mutations in 5 sarcomere genes. Contractile parameters were compared in 68 preclinical (Gϩ/LVHϪ), 40 overt (Gϩ/LVHϩ) subjects with HCM, and 38 mutation (Ϫ) normal control relatives. All subjects had normal left ventricular ejection fraction. In preclinical HCM, global and regional peak systolic strain ( sys ) and longitudinal systolic strain rate were not significantly different from controls, but early diastolic mitral annular velocity (Ea) was reduced by 13%. In overt HCM, there was a significant 27% and 14% decrease in global longitudinal sys and systolic strain rate, respectively, compared with both preclinical HCM and controls (PϽ0.013 for all comparisons), and a 33% reduction in Ea. Conclusions-Sarcomere mutations have disparate initial effects on diastolic and systolic functions. Preclinical HCM is characterized by impaired relaxation but preserved systolic strain. In contrast, both diastolic and longitudinal systolic abnormalities are present in overt disease despite normal ejection fraction. We propose that diastolic dysfunction is an early consequence of sarcomere mutations, whereas systolic dysfunction results from mutations combined with subsequent pathological remodeling. Identifying mechanistic pathways triggered by these mutations may begin to reshape the clinical paradigm for treatment, based on early diagnosis and disease prevention. (Circ Cardiovasc Genet. 2009;2:314-321.)
H ypertrophic cardiomyopathy (HCM) is caused by dominant mutations in sarcomere genes. 1, 2 Although the clinical manifestations are highly variable, HCM can be associated with serious consequences including sudden cardiac death and refractory heart failure. The diagnosis of HCM currently depends on identifying unexplained left ventricular hypertrophy (LVH); however, the penetrance of LVH is age-dependent, and LV wall thickness is typically normal early in life. 3, 4 Genetic testing allows identification of a novel and important population comprised of individuals in families with HCM who have inherited the disease-causing sarcomere mutation and are, therefore, at high risk for disease development but who have not yet manifested diagnostic features of HCM, specifically LVH. Better characterization of this in-triguing cohort, denoted preclinical HCM, will identify early effects of sarcomere mutations before the pathological cardiac remodeling that defines clinically overt disease.
Clinical Perspective on p 321
The precise effects of mutations in sarcomere proteins on contractile function in HCM have not been fully characterized. 5 Previous studies on animal models and preclinical human HCM demonstrated that diastolic function is impaired before LVH develops. 6 -9 Although these findings suggest that sarcomere mutations have direct and early consequences on diastolic function, the impact on systolic function has not been fully elucidated.
Unlike traditional measures of systolic function such as fractional shortening or ejection fraction (EF), the new modality of echocardiographic strain analysis offers the advantage of measuring indices directly from the ventricular myocardium, allowing improved quantification of global and regional function. 10 Systolic strain ( sys ) is a measure of deformation, expressed as the percent change in length of a myocardial segment, relative to end-diastolic length. 11 Systolic strain rate (SSR) is an early systolic index, which represents the rate of myocardial deformation and correlates with end-systolic elastance and peak dP/dt. 12 Nonangledependent speckle tracking techniques (2D strain) allow evaluation of the 3 principal components of cardiac strainradial, circumferential, and longitudinal. 13 Furthermore, echocardiographic strain imaging has revealed systolic dysfunction in patients with cardiac amyloidosis 14 or clinically defined HCM 15 despite preserved LVEF.
In this study, we use echocardiographic strain imaging to better characterize the early and late effects of sarcomere mutations on systolic function by evaluating genotyped subjects with preclinical and overt HCM.
Methods

Study Population
The study population consisted of genotyped HCM patients and relatives identified through research protocols or clinical evaluation at 3 centers in Boston, Mass (nϭ63), Copenhagen, Denmark (nϭ56), and Minneapolis, Minn (nϭ28). Genetic status was determined in all subjects by direct DNA sequencing of sarcomere genes. Families with at least 2 affected generations were recruited for participation, and echocardiographic studies were performed on available subjects. Participants were assigned to 3 status groups designated overt HCM, preclinical HCM, and normal control based on genotypic status and LV wall thickness. Because borderline LVH may indicate mild or early disease in individuals who carry a pathogenic sarcomere mutation, we used more rigorous criteria 16 than used for a routine clinical diagnosis of HCM to avoid the inclusion of individuals with mild or emerging cardiomyopathy in the preclinical group. Overt HCM was defined by the presence of a sarcomere gene mutation and maximal LV wall thickness of Ն12 mm, or Z score Ն2 in children. The preclinical HCM group consisted of family members who carried a mutation but who lacked LVH (maximal LV wall thickness Ͻ12 mm or Z score Ͻ2 in children). Control subjects were healthy relatives who did not carry a sarcomere mutation. Individuals were excluded if they had systemic hypertension (systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg or taking antihypertensive medication), LVEF Ͻ55%, coronary artery disease, valvular heart disease, previous septal myectomy or alcohol septal ablation, electronic ventricular pacing, or atrial fibrillation. Informed consent was obtained from all participants in protocols approved by the Institutional Review Boards of Brigham and Women's Hospital and Minneapolis Heart Institute Foundation and the Local Science Ethics Committee in Copenhagen, Denmark.
Echocardiographic Protocol
Vivid-7 ultrasound systems (GE Medical Systems, Milwaukee, Wis) were used to obtain standard 2D and Doppler echocardiographic images. Recordings were stored digitally and analyzed offline by 2 observers (C.Y.H. and J.J.T), blinded to status group designation. Measurements were made on the average of 3 cardiac cycles according to criteria established by the American Society of Echocardiography, 17 including cardiac dimensions, mitral inflow parameters, LVEF (modified Simpson method), and tissue Doppler myocardial velocities in systole (Sa) and early diastole (Ea). Global values of Ea and Sa represent the average of the lateral, septal, anterior, and inferior aspects of the mitral annulus, measured in the apical 4-and 2-chamber views.
Echocardiographic Strain Acquisition and Analysis
Longitudinal, radial, and circumferential strain was determined from apical and midventricular parasternal short-axis images. During image acquisition for longitudinal strain, frame rates were maximized by narrowing the sector to isolate individual walls (range, 40 to 85 frames per second). Off-line image analysis was performed using commercial software (EchoPAC 6.0, GE Medical Systems) with speckle tracking methodology (2D strain, GE Medical Systems), which tracks the movement of natural acoustic speckles in the myocardium from 2D gray-scale images. 13, 15, 18, 19 The endocardium was manually traced, and myocardial motion was tracked with automated software. Tracking quality was verified manually and with the software's automated quality grading scale. Segments were rejected if adequate quality could not be obtained despite manual correction. Representative 2D strain tracings are shown in Figure 1 .
Peak longitudinal systolic strain ( sys ) and SSR were measured in 12 segments from the basal, middle, and apical regions of the septal, lateral, anterior, and inferior walls from the apical 4-and 2-chamber views. Global values represent the average measurements from these 12 ventricular segments. Peak systolic radial and circumferential strains were measured in 6 segments from a midventricular parasternal short-axis image, using 2D strain. Global values represent the average measurements from 6 midventricular segments.
Statistical Analysis
To test for differences between the 3 status groups or between subjects with MYH7 and MYBPC3 mutations, ANOVA was performed adjusting for age and with clustering to adjust for the influence of relationships between family members. The GenMod procedure in SAS was used, assuming an exchangeable correlation structure. Basic clinical characteristics and conventional echocardiographic parameters are expressed as meanϮSD. Values for agedependent parameters of tissue Doppler and strain are expressed as adjusted meanϮage-and family-adjusted SE. A P value Ͻ0.017 was considered statistically significant to apply post hoc Bonferroni correction for multiple comparisons across the 3 status groups after age-adjusted and family-correlated analysis. To evaluate multiple predictors simultaneously and adjust for confounders, the preclinical HCM group was compared with the control group with a logistic regression model using the GenMod procedure, assuming an exchangeable correlation structure to account for family relations. Statistical analysis was performed with SAS version 9.1 (SAS Institute Inc, Cary, NC).
Results
Basic Clinical and Echocardiographic Characteristics
A total of 146 individuals from 47 families were analyzed, including 40 subjects with overt HCM, 68 subjects with preclinical HCM, and 38 mutation (Ϫ) healthy relatives as normal controls. Forty-one different mutations in 5 sarcomere genes were represented: ␤-myosin heavy chain (MYH7, nϭ51), cardiac myosin binding protein C (MYBPC3, nϭ40), cardiac troponin T (TNNT2, nϭ11), cardiac troponin I (TNNI3, nϭ5), and ␣-tropomyosin (TPM1, nϭ1; see the supplemental Table for a full listing of mutations). All mutations were known or presumed to be pathogenic by standard criteria of previous reports in the literature, appropriate cosegregation of the mutation, the absence of the mutation in large numbers of normal controls, alteration of evolutionarily conserved residues, and/or predicted impact on protein structure.
Basic clinical and echocardiographic parameters are summarized in Table 1 . All preclinical and control subjects were asymptomatic (New York Heart Association class I), not taking cardiac medications, and had normal conventional echocardiographic studies. Preclinical subjects were younger and had slightly lower blood pressure than controls. Standard cardiac dimensions were within normal limits for all preclinical and control subjects, although the preclinical HCM cohort had a slightly lower mean posterior wall thickness.
Consistent with its definition, the overt HCM cohort (nϭ40) had significantly greater LV wall thickness (mean maximal wall thickness, 20.0Ϯ5.0 mm) than the control and preclinical groups. In addition, LV cavity size was smaller and left atrial diameter larger. Seven percent of the population with overt HCM had resting obstructive physiology (peak LV intracavitary gradient Ն30 mm Hg), and the majority (83%) had asymmetrical septal hypertrophy. Subjects with overt disease had no or mild symptoms (85% New York Heart Association class I; 15% New York Heart Association class II). Thirty-two percent were taking cardiac medications (␤-blockers, nϭ8; L-type calcium channel blockers, nϭ4; disopyramide, nϭ1). Excluding individuals taking medications did not alter the results (data not shown). Thus, we believe that neither our results nor their interpretation were substantially influenced by cardioactive medication administration in a subset of the overt HCM cohort, and the data presented reflect analyses of the full cohort.
Echocardiographic Tissue Doppler and Strain Analysis
Echocardiographic strain and tissue Doppler peak velocity data are summarized in Table 2 . Interpretable 2D strain data were obtained in 89% of segments and 93% of walls; strain rate data were interpretable in 81% of segments and 82% of walls.
Systolic Strain and SSR Are Preserved in Preclinical HCM
In comparing preclinical HCM with normal controls, there was no significant difference in systolic function as reflected by global longitudinal, radial, or circumferential systolic strain, or longitudinal SSR ( Table 2 ). Evaluation of individual walls yielded the same results with no significant differences in regional longitudinal sys or SSR between the preclinical and control cohorts. Sa velocities were minimally decreased in the preclinical cohort. Because Sa may be influenced by apex to base LV length, 20 and there was a wide variation in age and body size in our population, and Sa was also normalized to LV length. Normalized values of Sa were not significantly different between the preclinical HCM and control cohorts. Results for global longitudinal strain and SSR are summarized in Figure 2 . 
Diastolic Function Is Disproportionately Decreased in Preclinical HCM and the Best Predictor of Genotype
Consistent with previous reports that focused on diastolic function, 8, 9 standard parameters of mitral inflow did not discriminate between preclinical HCM and control groups (data not shown), but global Ea velocity was significantly reduced by 13% in preclinical HCM (12.3Ϯ0.3 versus 14.2Ϯ0.3 cm/s, PϽ0.0001; Table 2 ), remaining significantly reduced if Ea was normalized for LV length. Multivariate logistic regression was performed, comparing preclinical HCM and controls, to identify predictors of carrying a gene mutation in these 2 cohorts with normal LV wall thickness. Age, gender, Ea, Sa, and global longitudinal sys were included in the final model. No metrics of LV systolic function (Sa velocity, global longitudinal sys , or SSR) were significant multivariate predictors of carrying a sarcomere mutation. After adjustment, only age and Ea velocity (but not the E/Ea ratio) remained independently predictive of genotype status (data not shown). Preclinical HCM subjects were significantly younger and had a lower Ea velocity than genotype (Ϫ) normal control relatives.
The performance of a reduced Ea velocity for identifying mutation carriers is summarized in Table 3 . Receiver operator curve analysis identified a global Ea velocity of 12 cm/s as the optimal threshold value for individuals 25 years and younger. EaՅ12 cm/s had an 86% positive predictive value for identifying young preclinical mutation carriers; however, the negative predictive value of EaϾ12 cm/s was only 22%. As such, low Ea has high specificity but low sensitivity for differentiating apparently healthy family members with sarcomere mutations.
Systolic and Diastolic Functions Are Reduced in Overt HCM Despite Normal LVEF
In subjects with overt HCM, longitudinal systolic strain and strain rate were substantially impaired (Figure 2 ) despite the presence of normal LVEF. Compared with normal controls, global longitudinal sys was reduced by 27% (Ϫ15.8Ϯ1.0% versus Ϫ21.5Ϯ0.5%, respectively, PϽ0.0001), and global longitudinal SSR was reduced by 14% (Ϫ1.21Ϯ0.05/s versus Ϫ1.41Ϯ0.05/s, respectively, Pϭ0.0008; Table 2 ). Global circumferential and radial sys did not significantly differ between any of the 3 cohorts. A further decline in diastolic function was noted with a 33% reduction global Ea velocity relative to controls and a 23% reduction relative to preclinical HCM ( Table 2) . Subjects with overt HCM were analyzed to determine whether the degree of LVH correlated to strain abnormalities or other features of disease. There was a significant inverse correlation between maximal LV wall thickness and global longitudinal SSR (Pearson rϭϪ0.52, Pϭ0.002) and sys (Pearson rϭϪ0.53, Pϭ0.0006). However, there was no significant association between the degree of LVH and global Sa or Ea velocities, or LVEF.
Comparison of Myosin Heavy Chain and Myosin Binding Protein C Mutations
Exploratory analyses were performed to compare subjects with mutations in the 2 most prevalent genes, myosin heavy chain and myosin binding protein C. Mutations in these genes accounted for 83% of all genotype positive subjects. In overt HCM, no significant differences were identified between individuals with mutations in MYH7 (nϭ17) and MYBPC3 (nϭ15), regarding age-adjusted metrics of diastolic (global Ea) or systolic function (global Sa, longitudinal sys , SSR, or LVEF; Table 4 ). However, a greater degree of LVH was associated with mutations in MYBPC3 compared with MYH7 (maximal LV wall thickness, 21.9Ϯ0.2 versus 17.7Ϯ0.1 cm, respectively, Pϭ0.03).
In age-adjusted analysis of the preclinical HCM cohort (MYH7, nϭ35; MYBPC3, nϭ24), subjects with MYH7 mu-tations had evidence of more impaired diastolic function but enhanced systolic function relative to subjects with MYBPC3 mutations ( Table 4 ). Global Ea was 9% lower in subjects with MYH7 mutations (12.8Ϯ0.4 versus 14.1Ϯ0.4 cm/s, respectively, Pϭ0.025) and global longitudinal sys was 10% higher (22.92Ϯ0.02% versus 20.82Ϯ0.58%, respectively, Pϭ0.004). Notably, global longitudinal sys in preclinical MYH7 subjects was also 9% higher than control subjects (23.14Ϯ0.43 versus 21.14Ϯ0.50, Pϭ0.001), whereas strain in preclinical MYBPC3 subjects did not differ from controls. However, no significant differences in global Sa or global longitudinal SSR in preclinical MYBPC3 or MYH7 HCM were identified.
Discussion
Pathogenesis of HCM: From Mutation to Disease
To better understand the early and late consequences of sarcomere mutations on cardiac function, echocardiographic strain parameters in preclinical mutation carriers without LVH were compared with individuals with overt HCM and normal controls. Our results provide insights into the pathogenesis of HCM, indicating that different patterns of contractile abnormalities are present in early and late disease. Preclinical HCM is characterized by diastolic dysfunction but preserved LV systolic function. In contrast, both diastolic and longitudinal systolic functions are substantially reduced in phenotypically overt HCM despite normal LVEF. We propose that although diastolic dysfunction occurs as an early conse- quence of the underlying sarcomere mutation, the development of systolic dysfunction is associated with not only the mutation but also the distinctive changes in myocardial architecture that accompany later development of clinical disease. Building on previous reports, 8, 9 our results provide further evidence that subtle myocardial dysfunction is present before the development of cardiac hypertrophy in preclinical HCM. Impaired relaxation is the predominant functional abnormality in preclinical HCM. In the context of family evaluation, reduced Ea velocity is the only identified parameter of cardiac function that predicts the presence of a sarcomere mutation in relatives without LVH. However, despite the biological significance of this parameter, its diagnostic sensitivity is low. Identifying normal Ea velocity does not exclude the possibility that an apparently healthy member of a family with HCM carries a sarcomere mutation.
The disparate early impact of sarcomere mutations on systolic and diastolic function in preclinical human HCM is strikingly similar to findings in a mouse model of HCM produced by targeted insertion of the pathogenic Arg403Gln missense mutation in the myosin heavy chain gene. 7 Detailed invasive hemodynamic studies directly assessed LV pressurevolume relations in intact animals. Before the development of LVH, young heterozygous mice showed decreased diastolic function (manifest as increased , time to peak filling, and end-diastolic elastance; decreased ϪdP/dt min ) but no significant differences in systolic function (dP/dt max , end-systolic elastance) as compared with age-matched wild-type controls. Although the molecular mechanisms by which sarcomere mutations impair diastolic function have not been fully elucidated, biophysical analyses of mutant proteins suggest that they result in slow actin-myosin dissociation kinetics with decreased rates of crossbridge detachment. 21 In animal models, these abnormalities have also been associated with altered intracellular calcium handling and decreased rates of Figure 2 . Global longitudinal systolic strain and strain rate preserved in preclinical HCM but decreased in overt HCM. Values for strain and strain rate are represented as meanϮSE adjusted for age and family relations. Left, There is no significant difference in global longitudinal strain in preclinical HCM compared to controls. Mean longitudinal strain was Ϫ21.8Ϯ0.5% in the preclinical HCM cohort and Ϫ21.5Ϯ0.5% in the control cohort (Pϭ0.66). Overt HCM was associated with a significant 27% reduction in peak longitudinal systolic strain (Ϫ15.8Ϯ1.0%, PϽ0.0001 versus both control and preclinical cohorts). Right, Similar results are seen for global longitudinal systolic strain rate. There is no significant difference between the preclinical and control cohorts (Ϫ1.38Ϯ0.04/s versus Ϫ1.41Ϯ0.05/s, respectively, Pϭ0.54). A significant 14% reduction in systolic strain rate was seen in the overt HCM cohort (SSR, Ϫ1.21Ϯ0.05/s; PϽ0.01 versus both control and preclinical cohorts). calcium reuptake into the sarcoplasmic reticulum 22, 23 ; biochemical findings that could impair relaxation. Notably in our human overt HCM cohort, no correlation was found between LVH and Ea velocity, further supporting the hypothesis that the fundamental mechanisms underlying diastolic dysfunction in HCM are not driven by cardiac hypertrophy. LVEF does not fully reflect contractile function in overt HCM. Despite the well-recognized normal or increased LVEF typically seen in overt HCM including our population, we demonstrate that longitudinal systolic dysfunction is present, with significant reductions in longitudinal peak systolic strain and SSR. As opposed to echocardiographic strain analysis, LVEF may not reflect impaired long-axis function; a metric that may be more sensitive to myocardial disease processes and reveal earlier changes in cardiac performance. 24 Our results for this population with genetically confirmed HCM corroborate previous studies using tagged cardiac MRI and echocardiographic strain in more heterogeneous (nongenotyped) cohorts that identified reduced longitudinal systolic strain in individuals with a clinical diagnosis of HCM. 15, [25] [26] [27] Similar findings have also been described in cardiac hypertrophy in a different disease, cardiac amyloidosis. Reduced longitudinal systolic strain and SSR were present in patients with normal EF and either no overt cardiac involvement or with clinical heart failure. 14, 28 The cause of impaired systolic function in overt HCM and the links connecting sarcomere mutation, the development of LVH, and the development of systolic dysfunction are unclear. Although it is possible that sarcomere mutations primarily result in slowly progressive or delayed decline in systolic function, triggering later development of compensatory LVH in overt HCM, we propose that the mutation in isolation is not sufficient to cause systolic abnormalities. Instead, both the mutation and the pathological remodeling that typifies overt disease, namely myocyte disarray, hypertrophy, and fibrosis, lead to the downstream development of perturbed active force generation. We base this proposal on 3 lines of evidence. First, biophysical studies on isolated mutant myosin molecules and myofilaments suggest that sarcomere mutations that cause HCM are activating, resulting in higher actin sliding velocity, higher actomyosin ATPase activity, and increased maximal force generation. 29, 30 This effect may be reflected in the enhanced systolic strain detected in our preclinical MYH7 subjects. Second, deficits in systolic strain are not an early consequence of sarcomere mutations because these parameters are normal in preclinical HCM. Third, animal models indicate that myocyte disarray and fibrosis develop later in life, coincidentally with the emergence of gross cardiac hypertrophy 6 and by extrapolation we presume that preclinical HCM in humans lacks substantial histopathology. In aggregate, these data implicate changes in myocardial architecture in the development of systolic dysfunction.
An important limitation of this study is that our results reflect contractile function in two distinct stages of disease, and therefore, do not allow characterization of the time course between the onset of systolic dysfunction and the development of left ventricular hypertrophy. Longitudinal studies to follow preclinical sarcomere mutation carriers over time are needed to fully describe the temporal sequence of phenotypic evolution. In addition, the small number of subjects with MYH7 and MYBPC3 mutations limits the precision and power of exploratory subgroup comparisons to characterize gene-specific findings. As such, the failure to detect significant differences between these mutation groups does not prove that no differences are present. Future studies with larger numbers of subjects will be performed to better study gene-specific differences in a phenotypic expression.
Conclusions and Implications
HCM is caused by mutations in contractile proteins, thus providing a remarkable opportunity to characterize how changes in the heart's molecular motor influence myocardial structure and function. Studying a unique cohort with preclinical HCM, identified via genetic testing, allowed interrogation of disease pathogenesis and the intrinsic functional consequences of sarcomere mutations that occur in advance cardiac remodeling. The predominant early effect of these mutations, before the development of cardiac hypertrophy, is diastolic dysfunction with preserved systolic function. In addition, these studies demonstrate that the extent of the cardiomyopathic process in overt HCM is not fully appreciated by assessing left ventricular EF. Impaired longitudinal systolic function is present in overt HCM despite normal LVEF and may arise not only from the mutation but also from the prototypic changes in myocardial architecture, which develop later with expression LVH. These results have potentially important clinical implications, suggesting that future strategies aimed at diminishing the development of myocyte disarray, fibrosis, and hypertrophy, starting in the preclinical stage, may attenuate loss of systolic function and retard progression to symptomatic heart failure in HCM.
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